Esketamine as Treatment for Chronic Pain Due to Endometriosis: a RCT Study

PHASE3RecruitingINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

March 1, 2024

Primary Completion Date

January 1, 2026

Study Completion Date

June 1, 2026

Conditions
EndometriosisChronic Pelvic Pain Syndrome
Interventions
DRUG

Esketamine hydrochloride

Esketamine dosing regimen is set at 0.1 mg/kg/h as starting dosage. Dosage will be gradually increased based on heart rate, oxygen saturation, blood pressure and side effects (e.g. nausea and dissociative effects) during a period of 8 hours to a maximum of 0.5 mg/kg/h (in steps of 0.1-0.3-0.5 mg/kg/hour). This dosage regimen is similar to that used earlier by Sigtermans et al. \[1\].

DRUG

Placebo

8 hour infusion with saline (NaCl 0.9%)

Trial Locations (1)

Unknown

RECRUITING

Nederlandse Endometriose Kliniek, Reinier de Graaf Gasthuis, Delft

All Listed Sponsors
lead

Reinier de Graaf Groep

OTHER